Wertilin 48mg Tablet SR contains Betahistine dihydrochloride, an active compound primarily indicated for the treatment of Ménière’s disease and vestibular vertigo. Betahistine acts as a histamine analogue, exerting its therapeutic effects by improving microcirculation in the inner ear, thereby reducing endolymphatic pressure and alleviating symptoms such as vertigo, tinnitus, and hearing loss associated with vestibular disorders. The sustained-release formulation of Wertilin 48mg ensures a gradual and prolonged release of the active ingredient, enhancing patient compliance by reducing dosing frequency and maintaining steady plasma concentrations. This medication is typically administered orally, with dosage tailored according to the severity of symptoms and patient response, under medical supervision. Wertilin is contraindicated in patients with pheochromocytoma and should be used cautiously in individuals with a history of peptic ulcers or asthma due to potential histamine-related side effects. Common adverse reactions may include headache, nausea, and gastrointestinal discomfort, which are generally mild and transient. Wertilin 48mg Tablet SR should be used as part of a comprehensive management plan for vestibular disorders, and patients are advised to consult their healthcare provider before initiating therapy to ensure appropriate use and monitoring.